NRx Pharma Stock Is Moving Higher On COVID-19 Candidate Data

NRx Pharmaceuticals Inc NRXP has announced an additional finding from its Phase 2b/3 trial investigating Zyesami (aviptadil) for critically ill COVID-19 patients with acute respiratory failure.
Previously announced results have focused on survival and recovery from respiratory failure at 60 days and Zyesami's role in preventing the rise in the inflammatory cytokine IL-6 (cytokine storm).
NRx's new analysis shows that patients treated with Zyesami demonstrated improved blood oxygen within a day of starting treatment.
The average difference in Respiratory Distress Ratio between those treated with aviptadil and placebo was clinically meaningful and statistically significant.
Related Content: NRx Pharma, Cardinal Health Ink Zyesami Distribution Pact.
Price Action: NRXP shares are up 6.36% at $14.89 during the market session on the last check Monday.